Intensive lipid-lowering therapy in coronary artery disease: implications of the REVERSAL and PROVE-IT trials

Bibliography

• NISSEN SE, TUZCU EM, SCHOENHAGEN P et al.: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. "AMA (2004) 291(9):1071–1080.
   PubMed Web of Science ®Google Scholar
• ••The REVERSAL trial. A double-blind,angiographic trial conducted to evaluate the effect of treatment with an aggressive lipid-lowering strategy versus a moderate lipid-lowering strategy on coronary atherosclerosis progression assessed using IVUS in patients with symptomatic CAD.
   Google Scholar
• CANNON CP, BRAUNWALD E, McCABE CH et al.: Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl. I Med. (2004) 350(15):1495–1504.
   PubMed Web of Science ®Google Scholar
• ••The PROVE IT trial. A double-blind,clinical outcome trial evaluating the efficacy of the two different approaches of lipid lowering (standard compared with aggressive) in patients with ACS on subsequent cardiovascular events.
   Google Scholar
• EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). "AMA (2001) 285:2486–2497.
   Google Scholar
• •This report represents the latest US guidelines that are challenged by the current two studies.
   Google Scholar
• DE BACKER G, AMBROSIONI E, BORCH-JOHNSEN K et al: European guidelines on cardiovascular disease and prevention in clinical practice. Atherosclerosis. (2003) 171:145–155.
   PubMed Web of Science ®Google Scholar
• •This report represents the latest European guidelines that are also challenged by the current two studies.
   Google Scholar
• STAMLER J, WENTWORTH D, NEATON JD: Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). "AMA (1986) 256:2823–2828.
   PubMed Web of Science ®Google Scholar
• GRUNDY SM: Statin trials and goals of cholesterol-lowering therapy. Circulation (1998) 97:1436–1439.
   PubMed Web of Science ®Google Scholar
• SACKS FM, MOYE LA, DAVIS BR et al: Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial. Circulation (1998) 97:1446–1452.
   PubMed Web of Science ®Google Scholar
• WEST OF SCOTLAND CORONARY PREVENTION STUDY GROUP: Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation (1998) 97:1440–1445.
   PubMed Web of Science ®Google Scholar
• PEDERSON TR, OLSSON AG, FAERGEMAN 0 et al.: Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Study (45). Circulation (1998) 97:1453–1460.
   Google Scholar
• THE LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHAEMIC DISEASE (LIPID) STUDY GROUP: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl. J. Med. (1998) 339:1349–1357.
   PubMed Web of Science ®Google Scholar
• DOWNS JR, CLEARFIELD M, WEIS S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. "AMA (1998) 279:1615–1622.
   Google Scholar
• HEART PROTECTION COLLABORATIVE STUDY GROUP: MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 individuals: a randomised placebo-controlled trial. Lancet (2002) 360:7–22.
   PubMed Web of Science ®Google Scholar
• •The world's largest ever cholesterol-lowering study, which showed that the benefits of a statin (simvastatin) were unequivocal in patients who have normal or low cholesterol but are still considered at high risk of CHD.
   Google Scholar
• SALAM AM: Expanding indications of statins; implications of the Heart Protection Study. Expert Opin. Investig. Drugs (2003) 12:509–513.
   PubMed Web of Science ®Google Scholar
• POST CORONARY ARTERY BYPASS GRAFT TRIAL INVESTIGATORS: The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation of obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl. J. Med. (1997) 336:153–162.
   PubMed Web of Science ®Google Scholar
• PITT B, WATERS D, BROWN WV et al: Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl. J. Med. (1999) 341:70–76.
   PubMed Web of Science ®Google Scholar
• BROWN WV, AVERT I: Can aggressive lipid-lowering therapy provide additional clinical benefit? Subgroup analysis of the Atorvastatin VErsus Revascularization Treatments (AVERT) trial. Ear: Heart J. (2000) 21(Suppl.):157(Abstract).
   Google Scholar
• SCHWARTZ GG, OLSSON AG, EZEKOWITZ MD et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. JAMA (2001) 285:1711–1718.
   Google Scholar
• STENESTRAND U, WALLENTIN L: For the Swedish Register of Cardiac Intensive Care (RIKS-HIA): early statin treatment following acute myocardial infarction and 1-year survival. "AMA (2001) 285:430–436.
   PubMed Web of Science ®Google Scholar
• ARONOW HD, TOPOL EJ, ROE MT et al.: Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet (2001) 357:1063–1068.
   PubMed Web of Science ®Google Scholar
• NEWBY LK, KRISTINSSON A, BHAPKAR MV et al.: Early statin initiation and outcomes in patients with acute coronary syndromes. "AMA (2002) 287:3087–3095.
   Google Scholar
• LIUZZO G, BIASUCCI LM, GALLIMORE JR et al: Enhanced inflammatory response in patients with preinfarction unstable angina. Am. Coll Cardiol (1999) 34:1696-1703. Affiliation Amar M Salam MB, BS, MRCP (UK) Department of Cardiology and Cardiovascular Surgery, Hamad Medical Corporation, PO Box 3050, Doha, Qatar Tel: +974 4392642; Fax: +974 4392454; E-mail: [email protected]
   Google Scholar